Substance specific to human PD-1

Details Substance specific to human PD-1 Substance specific to human PD-1

2011-08-16

2011-08-16

Ouspenski, Ilia (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Reexamination Certificate

active

07998479

ABSTRACT:
The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.

REFERENCES:
patent: 5932449 (1999-08-01), Emanuel et al.
patent: 6111079 (2000-08-01), Wylie et al.
patent: 6808710 (2004-10-01), Wood et al.
patent: 7029674 (2006-04-01), Carreno et al.
patent: 1334659 (2003-08-01), None
patent: 1445264 (2004-08-01), None
patent: 01/14557 (2001-03-01), None
patent: 01/64249 (2001-09-01), None
patent: 02/078731 (2002-10-01), None
Supplemental European Search Report issued Apr. 11, 2006 in EP 04704324.5.
Gordon J. Freeman et al., “Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation”, J. Exp. Med., 2000, 192(7): 1027-1034.
Engin Ozkaynak et al., “Programmed Death-1 Targeting Can Promote Allograft Survival”, The Journal of Immunology, 2002, 169:6546-6553.
Laura L. Carter et al., “PD-1: PD-L inhibitory pathway affects both CD4 and CD8 T cells and is overcome by IL-2”, Eur. J. Immunol., 2002, 32: 634-643.
Margitta Alt et al., “Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobin y1 Fc or CH3 region”, FEBS Letters, 1999, 454: 90-94.
Peter J. Hudson et al., “High avidity scFv multimers; diabodies and triabodies”, Journal of Immunological Methods, 1999, 231: 177-189.
Sequence Alignment, Sequence 18 of U.S. Patent No. 6,111,079, 2008.
Tina Volkel et al., “Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies”, Protein Engineering, 2001, 14(10): 815-823.
Ziwei Huang, “Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis”, Pharmacology & Therapeutics, 2000, 86:201-215.
Teresa K. Attwood, “The Babel of Bioinfomatics”, Science, 2000, 290: 471-473.
Jeffrey Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era”, Trends in Biotech, 2000, 18(1): 34-39.
Bruce R. Blazar et al., “Infusion of Anti-B7.1 (CD80) and Anti-B7.2 (CD86) Monoclonal Antibodies Inhibits Murine Graft-Versus-Host Disease Lethality in Part Via Direct Effects on CD4+and CD8+T Cells”, The Journal of Immunology, 1996, 157: 3250-3259.

Affiliated with

Also associated with

Rating

Substance specific to human PD-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substance specific to human PD-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substance specific to human PD-1 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2792087